Home Based Daratumumab Administration for Patients with Multiple ...

Open label single arm study to assess the implementation of home ...

Herein, we propose a home-based subcutaneous daratumumab and hyaluronidase-fihj (dara) program for patients with MM. We hypothesize that this ...

Description. This phase II trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro ...

Open label single arm study to assess the implementation of home ...

Open label single arm study to assess the implementation of home based daratumumab administration in patients being treated for multiple myeloma. Adam F ...

Home Based Daratumumab Administration for Patients With Multiple ...

This clinical trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro is a ...

Best Practice for the Administration of Daratumumab in Multiple ...

As a result, it is important to provide relevant information about daratumumab treatment to patients. This should include its route of administration, hospital ...

ineligible patients who are newly diagnosed with multiple myeloma

Since 2020, the National Comprehensive Cancer Network® (NCCN®) has recommended daratumumab-based combination regimens for the treatment of newly ...

Open label single arm study to assess the implementation of home ...

... home based daratumumab administration in patients being treated for multiple myeloma. | TPS1609 Background: Multiple myeloma (MM) is an ...

Daratumumab Plus Standard Therapy for Multiple Myeloma - NCI

A large randomized clinical trial for people newly diagnosed with multiple myeloma has found that adding the drug daratumumab (Darzalex) to a standard ...

Home Based Daratumumab Administration for Patients With Multiple ...

Terms of Service. close. CLIN is intended for personal, non-commercial use only. By accessing this site without logging in, you agree not to use any content, ...

Analysis Finds Daratumumab Combo Offers Better PFS Than ...

The trial (NCT05511428) will study home-based subcutaneous daratumumab and hyaluronidase-fihj, sold as Darzalex Faspro, for patients with MM.

HealthTree

This clinical trial tests the treatment effect of home based daratumumab administration in treating patients with multiple myeloma. Darzalex Faspro is a ...

Real-world Duration of Use and Dosing Frequency of Daratumumab ...

Daratumumab (DARA) is an anti-CD38 monoclonal antibody approved as a combination therapy for newly diagnosed multiple myeloma (MM) and as ...

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple ...

Administration - Darzalex

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) is indicated for the treatment of adult patients with multiple myeloma: In combination with bortezomib, ...

Real-World Observations and Practical Considerations of ...

Background: Subcutaneous daratumumab (dara-SC) has several advantages over intravenous daratumumab (dara-IV). It has significantly shorter ...

FDA approves daratumumab and hyaluronidase-fihj for multiple ...

On May 1, 2020, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients ...

Safety of SC Daratumumab in the Treatment of Plasma-Cell Disorders

We suggest that patients who are receiving their first dose of SC daratumumab be monitored for 1 hour after administration. Monitoring is not necessary for ...

Daratumumab Utilization and Cost Analysis among Patients with ...

Conclusion: Daratumumab is utilized more frequently than the FDA-recommended dosing, leading to higher multiple myeloma treatment costs. Lay abstract. Since its ...

Home is best. Self-administration of subcutaneous Bortezomib at ...

Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma - A mixed ... Daratumumab, would not be selected for home ...

Transition from Intravenous to Subcutaneous Daratumumab ...

None of the patients included herein required rescue home medications or visited the emergency department within 24 to 48 hours after subcutaneous daratumumab ...